Welcome to our dedicated page for Basel Medical Group SEC filings (Ticker: BMGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Basel Medical Group Ltd filings document its foreign private issuer reporting, Nasdaq listing-rule compliance, governance changes and corporate transactions. Form 6-K current reports cover periodic-filing compliance, minimum bid price notifications, board and executive appointments or resignations, and changes in the company's independent registered public accounting firm.
The company's SEC disclosures also record financing-related lock-up waivers, Form 20-F reporting matters, and the completed acquisition of Bethesda Medical as a wholly owned indirect subsidiary. These filings provide formal disclosure on the company's Singapore healthcare operations, capital-structure actions, audit oversight, governance structure and material events affecting its listed ordinary shares.
Basel Medical Group Ltd has appointed Mr. Neo Chun How Alton as its new interim Chief Financial Officer, effective June 2, 2026. He replaces Ms. Jianing Lu, who resigned as CFO, with the Board expressing appreciation for her service.
Mr. Neo brings experience in corporate leadership, financial management, and education. He previously served as deputy CEO of InCorp Global’s Singapore operations, worked on tax policy at Singapore’s Ministry of Finance, helped develop the Singapore Chartered Accountant Qualification Programme, and teaches accounting-related courses at tertiary institutions. He holds an MBA from the University of Hull and multiple professional accounting and valuation memberships.
Basel Medical Group Ltd director Soong Kwek Yoon has filed a Form 3, which is an initial statement of beneficial ownership for insiders. The filing lists him as a director and not a ten percent owner, and does not report any transactions in company securities.
Basel Medical Group Ltd Chief Financial Officer Lu Jianing JN has filed an initial insider ownership report on Form 3. The filing lists no buy or sell transactions, and shows no derivative securities positions reported for this insider at this time.
Basel Medical Group Ltd director Tony Chen filed an initial Form 3 statement of beneficial ownership. The filing lists him as a director of BMGL but shows no reported transactions or derivative positions in this data, indicating only an initial disclosure of insider status.
Basel Medical Group Ltd Chief Executive Officer Chhoa Darren Yen Feng has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing excerpt shows no reported transactions and no listed derivative positions for the reporting person.
Basel Medical Group Ltd director and Chief Commercial Officer Tan Boon Chye (Darren) filed an initial ownership report showing indirect holdings in the company’s ordinary shares. A Singapore variable capital company, Rainforest Capital VCC, holds 10,205,229 ordinary shares on behalf of four subfunds.
One subfund, Basel Medical Fund, lists Tan Boon Chye as an ultimate beneficial owner, so he may be deemed to beneficially own a portion of these shares. He expressly disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest, and the filing does not report any new purchase or sale.
Basel Medical Group Ltd director Fung Keng Leong filed an initial ownership report showing indirect holdings of the company’s ordinary shares. The filing states that Rainforest Capital VCC, a Singapore variable capital company, holds 10,205,229 ordinary shares of Basel Medical Group Ltd on behalf of four subfunds.
The footnote explains that Fung is an ultimate beneficial owner of the Basel Medical Fund subfund and may be deemed to beneficially own the shares that Rainforest Capital VCC holds for that subfund. He disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest in them.
Basel Medical Group Ltd reported a change in its board of directors. The company appointed its Chief Commercial Officer, Mr. Tan Boon Chye (Darren), as a director on the board. He replaces Ms. Jianing Lu, who resigned as a director on the same day but continues to serve as the company’s Chief Financial Officer.
Basel Medical Group Ltd reports that Nasdaq has confirmed the company is now in full compliance with the exchange’s periodic filing requirement under Listing Rule 5250(c)(1). This follows Basel Medical’s amended Form 20-F for fiscal year 2025, filed on March 13, 2026, and means the prior filing-related deficiency has been resolved.
The company continues operating as a Singapore-based medical services group focused on orthopedic, neurosurgical and general healthcare, serving corporate and individual patients across multiple clinic locations in Singapore.
Basel Medical Group Ltd has filed Amendment No. 1 to its Form 20-F for the year ended June 30, 2025, to amend and restate key narrative sections and its audited consolidated financial statements for FY2024 and FY2025, and to file a new audit report from NLA DFK Assurance PAC.
The company updates risk factors, business overview, organizational structure, related party transactions and principal accountant fee disclosures, and refiles its list of subsidiaries as of March 13, 2026. Basel Medical, a BVI-incorporated orthopedic and sports medicine group operating in Singapore, had 18,785,750 ordinary shares outstanding as of June 30, 2025, and highlights extensive business, regulatory, data security and governance risks tied to its public listing, foreign private issuer and controlled company status.